LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 99

Search options

  1. Article: Het neurovasculair costoclaviculair compressiesyndroom bestaat niet.

    Banga, J D

    Nederlands tijdschrift voor geneeskunde

    2008  Volume 152, Issue 9, Page(s) 503

    Abstract: The term 'neurovascular compression syndrome' refers to a heterogeneous group of signs and symptoms thought to be generated by the compression of arteries, veins or nerves, which is caused by the anatomical relationships of muscles, ligaments and bony ... ...

    Title translation The neurovascular costoclavicular compression syndrome does not exist.
    Abstract The term 'neurovascular compression syndrome' refers to a heterogeneous group of signs and symptoms thought to be generated by the compression of arteries, veins or nerves, which is caused by the anatomical relationships of muscles, ligaments and bony structures in the thoracic outlet. Most cases are related to nerve compression; arterial and venous compression accounts for 1-3% of cases. The term 'neurovascular compression syndrome', which does not refer to a single entity, is confusing and should be avoided. Rather, a clinical problem thought to arise in the thoracic outlet should be described in terms of the underlying arterial, venous or nerve impairment. Indications for surgical intervention are limited: there is no evidence to suggest that patients who undergo surgery fare better than those who receive non-surgical treatment.
    MeSH term(s) Humans ; Prognosis ; Ribs/surgery ; Subclavian Artery/surgery ; Subclavian Vein/surgery ; Thoracic Outlet Syndrome/diagnosis ; Thoracic Outlet Syndrome/surgery ; Treatment Outcome
    Language Dutch
    Publishing date 2008-03-01
    Publishing country Netherlands
    Document type English Abstract ; Journal Article
    ZDB-ID 82073-8
    ISSN 1876-8784 ; 0028-2162
    ISSN (online) 1876-8784
    ISSN 0028-2162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Coagulation and fibrinolysis in diabetes.

    Banga, J D

    Seminars in vascular medicine

    2002  Volume 2, Issue 1, Page(s) 75–86

    Abstract: The accelerated development of atherothrombotic cardiovascular disease in type 2 diabetes mellitus may be enhanced by the presence of a prothrombotic state. This prothrombotic state includes a diminished fibrinolytic capacity and an increased ... ...

    Abstract The accelerated development of atherothrombotic cardiovascular disease in type 2 diabetes mellitus may be enhanced by the presence of a prothrombotic state. This prothrombotic state includes a diminished fibrinolytic capacity and an increased coagulability. Impaired fibrinolytic capacity appears to be a hallmark of the metabolic syndrome of type 2 diabetes and can be a direct consequence of visceral obesity. In addition, a chronic low inflammatory state with hyperinsulinemia and dyslipidemia may further influence the hemostatic balance. The characteristic dyslipidemia of type 2 diabetes, coined the atherogenic lipoprotein profile, with raised plasma levels of fasting and postprandial triglyceride lipoproteins, atherogenic low-density lipoproteins, and low high-density lipoproteins, is involved in promoting a hypercoagulable state. Lifestyle and pharmacologic interventions that reduce cardiovascular risk in the general population and that may improve the metabolic syndrome may also reduce the prothrombotic state.
    MeSH term(s) Arteriosclerosis/etiology ; Arteriosclerosis/physiopathology ; Blood Coagulation/physiology ; Blood Platelets/physiology ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/physiopathology ; Fibrinolysis/physiology ; Hemostasis/physiology ; Humans ; Insulin/physiology ; Lipid Metabolism ; Metabolic Syndrome/physiopathology ; Obesity/physiopathology ; Thrombosis/etiology ; Thrombosis/physiopathology
    Chemical Substances Insulin
    Language English
    Publishing date 2002-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2055723-1
    ISSN 1529-3505 ; 1528-9648
    ISSN (online) 1529-3505
    ISSN 1528-9648
    DOI 10.1055/s-2002-23098
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Myotoxiciteit en rhabdomyolysis ten gevolge van statinen.

    Banga, J D

    Nederlands tijdschrift voor geneeskunde

    2001  Volume 145, Issue 49, Page(s) 2371–2376

    Abstract: Rhabdomyolysis is a rare but potentially fatal complication associated with the use of cholesterol synthesis inhibitors (statins). The complication can develop in susceptible patients and with the concomitant use of medications that impede the ... ...

    Title translation Myotoxicity and rhabdomyolisis due to statins.
    Abstract Rhabdomyolysis is a rare but potentially fatal complication associated with the use of cholesterol synthesis inhibitors (statins). The complication can develop in susceptible patients and with the concomitant use of medications that impede the biodegradation of statins, for example, biotransformation via the cytochrome P450 system. This may result in the plasma and tissue concentrations of statins, and their active metabolites, increasing to levels that are toxic for striated muscle. Myopathy is present when plasma activity levels of creatinine kinase are raised to in excess of 10 times the upper limit of the normal value. Muscular complaints which may be indicative of myotoxicity and subsequent myopathy are present in 1-7% of statin users. Albeit to varying degrees, all statins can induce myotoxicity especially at high dosages. Rhabdomyolysis was clearly more prevalent under cerivastatin users than the users of other statins and was therefore recently withdrawn from the market. Statins should be withdrawn immediately if myopathy is suspected. Prompt withdrawal may prevent rhabdomyolysis.
    MeSH term(s) Creatine Kinase/blood ; Cytochrome P-450 CYP3A ; Cytochrome P-450 Enzyme System/drug effects ; Cytochrome P-450 Enzyme System/metabolism ; Drug Interactions ; Drug Therapy, Combination ; Drug and Narcotic Control ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hyperlipidemias/drug therapy ; Mixed Function Oxygenases/drug effects ; Mixed Function Oxygenases/metabolism ; Muscular Diseases/chemically induced ; Muscular Diseases/enzymology ; Netherlands ; Pyridines/adverse effects ; Rhabdomyolysis/chemically induced ; Rhabdomyolysis/enzymology
    Chemical Substances Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Pyridines ; Cytochrome P-450 Enzyme System (9035-51-2) ; cerivastatin (AM91H2KS67) ; Mixed Function Oxygenases (EC 1.-) ; CYP3A protein, human (EC 1.14.14.1) ; Cytochrome P-450 CYP3A (EC 1.14.14.1) ; Creatine Kinase (EC 2.7.3.2)
    Language Dutch
    Publishing date 2001-12-08
    Publishing country Netherlands
    Document type English Abstract ; Journal Article ; Review
    ZDB-ID 82073-8
    ISSN 1876-8784 ; 0028-2162
    ISSN (online) 1876-8784
    ISSN 0028-2162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Therapeutische angiogenese door intramusculaire toediening van het gen voor vasculaire endotheliale groeifactor (VEGF).

    Banga, J D

    Nederlands tijdschrift voor geneeskunde

    2000  Volume 144, Issue 3, Page(s) 113–116

    Abstract: Therapeutic angiogenesis by injection of growth factors or genes encoding for these appears a promising strategy for treatment of critical limb ischaemia but is currently still in an experimental phase. Among the cytokines that promote angiogenesis, i.e. ...

    Title translation Therapeutic angiogenesis through intramuscular injection of the gene for vascular endothelial growth factor (VEGF).
    Abstract Therapeutic angiogenesis by injection of growth factors or genes encoding for these appears a promising strategy for treatment of critical limb ischaemia but is currently still in an experimental phase. Among the cytokines that promote angiogenesis, i.e. the postnatal growth of blood vessels due to activation and proliferation of endothelial cells, vascular endothelial growth factor (VEGF) takes a special position. VEGF has proven to be a powerful angiogenic factor in vivo that specifically promotes migration and replication of endothelial cells. The specificity of VEGF for endothelial cells, compared with the more widespread effects of other factors such as fibroblast growth factor (FGF), may provide a broader therapeutic potential. The recombinant form of the human VEGF gene can be injected intramuscularly as a plasmid (phVEGF). The angiogenic effect of phVEGF can be explained in several ways: by direct stimulation of proliferation and migration of endothelial cells in vivo; by recruitment of previously existing collaterals; and by improving vasomotor function of vessels in ischaemic tissue.
    MeSH term(s) Animals ; Endothelial Growth Factors/administration & dosage ; Endothelial Growth Factors/therapeutic use ; Endothelium, Vascular/drug effects ; Genetic Therapy/methods ; Humans ; Injections, Intramuscular ; Ischemia/therapy ; Lymphokines/administration & dosage ; Lymphokines/therapeutic use ; Neovascularization, Physiologic/genetics ; Peripheral Vascular Diseases/therapy ; Protein Isoforms/administration & dosage ; Protein Isoforms/therapeutic use ; Regeneration ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors
    Chemical Substances Endothelial Growth Factors ; Lymphokines ; Protein Isoforms ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors
    Language Dutch
    Publishing date 2000-01-15
    Publishing country Netherlands
    Document type English Abstract ; Journal Article ; Review
    ZDB-ID 82073-8
    ISSN 1876-8784 ; 0028-2162
    ISSN (online) 1876-8784
    ISSN 0028-2162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Popping pneumothorax.

    Remmelts, H H F / Banga, J D

    The Netherlands journal of medicine

    2010  Volume 68, Issue 4, Page(s) 187

    MeSH term(s) Acetaminophen/therapeutic use ; Adult ; Analgesics, Non-Narcotic/therapeutic use ; Chest Pain/drug therapy ; Chest Pain/etiology ; Heart Auscultation ; Humans ; Male ; Pneumothorax/complications ; Pneumothorax/diagnosis ; Pneumothorax/diagnostic imaging ; Radiography
    Chemical Substances Analgesics, Non-Narcotic ; Acetaminophen (362O9ITL9D)
    Language English
    Publishing date 2010-04
    Publishing country Netherlands
    Document type Case Reports ; Letter
    ZDB-ID 193149-0
    ISSN 1872-9061 ; 0300-2977
    ISSN (online) 1872-9061
    ISSN 0300-2977
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Coagulation and Fibrinolysis in Diabetes

    Banga, J. D.

    Seminars in Vascular Medicine

    2002  Volume 2, Issue 01, Page(s) 75–86

    Abstract: The accelerated development of atherothrombotic cardiovascular disease in type 2 diabetes mellitus may be enhanced by the presence of a prothrombotic state. This prothrombotic state includes a diminished fibrinolytic capacity and an increased ... ...

    Abstract The accelerated development of atherothrombotic cardiovascular disease in type 2 diabetes mellitus may be enhanced by the presence of a prothrombotic state. This prothrombotic state includes a diminished fibrinolytic capacity and an increased coagulability. Impaired fibrinolytic capacity appears to be a hallmark of the metabolic syndrome of type 2 diabetes and can be a direct consequence of visceral obesity. In addition, a chronic low inflammatory state with hyperinsulinemia and dyslipidemia may further influence the hemostatic balance. The characteristic dyslipidemia of type 2 diabetes, coined the atherogenic lipoprotein profile, with raised plasma levels of fasting and postprandial triglyceride lipoproteins, atherogenic low-density lipoproteins, and low high-density lipoproteins, is involved in promoting a hypercoagulable state. Lifestyle and pharmacologic interventions that reduce cardiovascular risk in the general population and that may improve the metabolic syndrome may also reduce the prothrombotic state.
    Keywords Metabolic syndrome ; type 2 diabetes ; fibrinolysis ; coagulation ; dyslipidemia
    Language English
    Publishing date 2002-01-01
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2055723-1
    ISSN 1529-3505 ; 1528-9648
    ISSN (online) 1529-3505
    ISSN 1528-9648
    DOI 10.1055/s-2002-23098
    Database Thieme publisher's database

    More links

    Kategorien

  7. Article: Who doesn't need vascular medicine?--A team approach to vascular care and the role for vascular medicine.

    Banga, J D

    European journal of vascular surgery

    1993  Volume 7, Issue 1, Page(s) 3–5

    MeSH term(s) Angioplasty, Balloon ; Combined Modality Therapy ; Humans ; Patient Care Team ; Physician's Role ; Prognosis ; Vascular Diseases/etiology ; Vascular Diseases/therapy ; Vascular Surgical Procedures
    Language English
    Publishing date 1993-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 639235-0
    ISSN 0950-821X
    ISSN 0950-821X
    DOI 10.1016/s0950-821x(05)80534-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Foreword: vascular medicine in The Netherlands: a specialism getting "hands and feet".

    Banga, J D

    VASA. Supplementum

    1992  Volume 34, Page(s) 4–6

    MeSH term(s) History, 20th Century ; Humans ; Internal Medicine/history ; Netherlands ; Specialization/trends ; Vascular Diseases/history
    Language English
    Publishing date 1992
    Publishing country Switzerland
    Document type Biography ; Historical Article ; Journal Article ; Portrait
    ISSN 0251-1029
    ISSN 0251-1029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Book ; Conference proceedings: State of the art lectures / 64. European Atherosclerosis Society Congress : Utrecht, 10-13 June 1995

    Banga, J.D

    (Atherosclerosis ; 118, Suppl.)

    1995  

    Institution European Atherosclerosis Society
    Event/congress European Atherosclerosis Society Congress (64, 1995.06.10-13, Utrecht)
    Author's details guest eds.: J. D. Banga
    Series title Atherosclerosis ; 118, Suppl.
    Language English
    Size S149 S, Ill., graph. Darst
    Publisher Elsevier
    Publishing place Amsterdam u.a.
    Document type Book ; Conference proceedings
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  10. Article: Urinary sex hormone excretions in premenopausal women and coronary heart disease risk: A nested case-referent study in the DOM-cohort

    Banga, J. D.

    J. Clinical Epidemiology

    1997  Volume 50, Issue 3, Page(s) 275–281

    Institution P.O. Box 85500, NL-3508 GA Utrecht c/o Dr. J.D. Banga, Department of Internal Medicine, Academic Hospital Utrecht
    Keywords Koronarsklerose ; Frau ; Sexualhormon ; Lebensalter ; Risiko ; Klimakterium ; Ovulation ; Inzidenz
    Language English
    Document type Article
    ZDB-ID 639306-8
    ISSN 0895-4356 ; 1878-5921 ; 0895-4356
    ISSN (online) 0895-4356 ; 1878-5921
    ISSN 0895-4356
    Database Social Medicine (SOMED)

    Kategorien

To top